drugset / Trial / NCT06258356
Remimazolam in High Risk ERCP Patients
RandomizedParallel-groupQuadruple-blindOther
Summary
We conducted a randomized trial to investigate whether the administration of Remimazolam in patients undergoing high-risk endoscopic retrograde cholangiopancreatography (ERCP) could significantly reduce the occurrence of intraoperative hypotension, facilitate rapid induction, and result in fewer associated complications.
Timeline
- Start
- 2024-02-15
- Primary completion
- 2028-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remimazolam | Small molecule | — | — |
Indications
No indication recorded.